Kovack Advisors Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 38.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,279 shares of the company’s stock after acquiring an additional 6,787 shares during the period. Kovack Advisors Inc.’s holdings in Johnson & Johnson were worth $4,019,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of JNJ. MTM Investment Management LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the first quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after purchasing an additional 61 shares during the period. OneAscent Financial Services LLC raised its holdings in shares of Johnson & Johnson by 3.3% during the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after purchasing an additional 63 shares during the period. Beech Hill Advisors Inc. raised its holdings in shares of Johnson & Johnson by 0.3% during the second quarter. Beech Hill Advisors Inc. now owns 23,595 shares of the company’s stock worth $3,906,000 after purchasing an additional 63 shares during the period. MBE Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 3.4% during the second quarter. MBE Wealth Management LLC now owns 1,929 shares of the company’s stock worth $319,000 after purchasing an additional 63 shares during the period. Finally, FIDELIS iM LLC raised its holdings in shares of Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after purchasing an additional 64 shares during the period. Hedge funds and other institutional investors own 68.40% of the company’s stock.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $157.64 on Monday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $164.30 and a 200-day moving average of $162.40. The firm has a market cap of $409.70 billion, a price-to-earnings ratio of 31.91, a price-to-earnings-growth ratio of 3.19 and a beta of 0.55.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 29th. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Atlantic Securities upped their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Finally, Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research report on Thursday, August 31st. Nine investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $171.06.
Check Out Our Latest Analysis on JNJ
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Invest in Semiconductors
- How To Find Value Stocks Using This Simple Filtering Method
- What is Forex and How Does it Work?
- MarketBeat Week in Review – 10/2 – 10/6
- What is the Dow Jones Industrial Average (DJIA)?
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
